Tag: Liver
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
Progression-free survival significantly improved in unresectable hepatocellular carcinoma versus TACE alone
Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
Higher odds of receiving DAA treatment seen for younger age, being seen by a gastroenterologist or infectious disease physician, having cirrhosis
Increasing Generational Status Linked to Elevated Risk for Liver Cancer
Increased risk in second- and third- versus first-generation Mexican Americans mainly seen in men
Hepatitis C Virus Still Leading Cause of Hepatocellular Cancer in Men
Since 2017, leading cause of HCC is NAFLD among women; increases in ALD- and NAFLD-HCC seen since 2015
Sugar-Sweetened Drinks Linked to Increased Incidence of Liver Cancer, Mortality
Incidence of liver cancer and death from chronic liver disease increased for postmenopausal women drinking one or more sugar-sweetened beverage per day
ChatGPT Provides Some Helpful Responses for Liver Diseases
However, responses were lower for comprehensiveness and knowledge of guideline variations
AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer
Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation
Robotic Resection Cuts Perioperative Morbidity With Liver Cancer
Overall survival and cumulative incidence of death related to tumor recurrence similar to open resection
Liver Cancer in Top Five Causes of Cancer Deaths in 90 Countries
The number of people diagnosed with liver cancer is predicted to rise substantially by 2040
Liver Cancer Risk May Rise for 2nd-, 3rd-Generation U.S. Mexicans
Risk of hepatocellular carcinoma increased by 35 and 61 percent for second-, third- versus first-generation U.S. Mexicans
